Bristol-Myers Suspends Hepatitis C Drug Clinical Trial
This article is for subscribers only.
Bristol-Myers Squibb Co. lost ground in the race to develop a stand-alone hepatitis C pill after the company suspended testing of an experimental drug that cost it $2.5 billion to acquire earlier this year.
Bristol fell the most in 10 years after the New York-based company said yesterday it wouldn’t continue to administer the therapy, known as BMS-986094, after a patient developed heart failure, what the drugmaker called a “serious safety issue” in a statement.